Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") is pleased to provide this corporate update on the Company's execution expanding its powerful chronic-disease screening and reporting platform, HealthTab.

On August 8 th , the Company announced a new Master Service Agreement and Statement of Work was signed with Shoppers Drug Mart pharmacies to significantly expand the HealthTab point-of-care testing platform to up to 450 locations nation-wide, with affiliated locations under the Loblaw family of brands being included.

"The team has been exceptional in deploying systems and we have already deployed more than half of the target locations," said Hector Bremner, Avricore Health's CEO. "We are on track to achieve the late-November target for full deployment."

Once a pharmacy has HealthTab onsite there is a period of training and acclimating teams with the workflow. Nevertheless, data from locations is indicating strong utilization and patient uptake, generating strong consumables-based revenues.

In fact, HealthTab already has positive cash-flow from operations and is expected to significantly ramp up gross revenues over the next 12 months yielding target margins and profitability by Q2 2023.

Supporting the optimism of strong and sustainable growth are the anticipated policy and funding announcements related to point-of-care in community pharmacy by the federal and provincial governments in the coming weeks and months. These changes and commitments will have a significant impact on sales volumes in 2023, not to mention demand from pharmacy groups to install HealthTab.

For example, on October 5 th , the Government of Canada tabled its Framework for Diabetes in Canada, which lays out an aggressive strategy to better screen, surveil, prevent, and manage this disease which currently costs $30 Billion CAD annually to treat. To find the details, please visit: https://www.canada.ca/en/public-health/services/publications/diseases-conditions/framework-diabetes-canada.html

Also, in addition to Alberta and Ontario, British Columbia recently announced their plan to expand the scope of pharmacy practice, which includes limited prescribing as of October 14 th , and makes further commitments to work with the profession to identify additional ways they can contribute to healthcare solutions, such as chronic disease screening and support, as in other jurisdictions. To learn more, please visit: https://news.gov.bc.ca/releases/2022HLTH0059-001464

Internationally, policy and funding supporting more scope for pharmacists to tackle chronic disease and alleviate the pressures being faced for primary care also give a great deal of confidence that HealthTab's objective of being the world's leading point-of-care solution for pharmacy has a bright future. The coming weeks and months are expected to bring positive news and new opportunities for our current EU, UK and US program initiatives.

HealthTab™ is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab™ has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19. The HealthTab™ network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third-party app integration through API.

Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab™, a wholly owned subsidiary, the company's mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies.

Avricore Health Inc. Hector Bremner, CEO 604-773-8943 info@avricorehealth.com www.avricorehealth.com

Cautionary Note Regarding Forward-Looking Statements Information in this press release that involves Avricore Health's expectations, plans, intentions, or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release.

Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a few risks, uncertainties, and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy

News Provided by GlobeNewswire via QuoteMedia

In 2020, the global point-of-care testing (POCT) market was valued at US 34.49 Billion and expected to expand at an annual growth rate (CAGR) of 9.4 percent to reach a projected US 81.37 Billion by 2028. The upsurge will be driven largely by increased demand for screening and managing chronic diseases as well as rapidly assessing infectious diseases such as COVID-19.

The accessibility of POCT has been an increasing priority of the world’s leading health organizations and experts. Pharmacies are ideal ‘hubs’ within the community to offer patients better access to the numbers they need to know for preventing or treating conditions such as diabetes and heart disease or the timely diagnosis of infection.

Avricore Health Inc. (TSXV:AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab™ (a wholly owned subsidiary), its mission is to make actionable health information more accessible to everyone by creating the world’s largest network of rapid testing devices in community pharmacies.

HealthTab™ is a turnkey point-of-care testing solution that effectively turns pharmacies into diagnostic hubs (sometimes known as ‘Community Diagnostic Centres’ or CDCs) and connects them on a single, cloud-based platform.

The HealthTab™ network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including: equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third party app integration through API.In June 2021, Avricore signed a Master Agreement with select Shoppers Drug Mart pharmacies to pilot the HealthTab™ platform. This agreement allows patients access to point-of-care blood screening and health-data management for potential risks for developing diabetes and cardiovascular conditions through the HealthTab™-integrated Afinion 2™ analyzers by Abbott Rapid Diagnostics.

Avricore is the first pharmacy solutions provider to partner with Abbott (NYSE:ABT), the global healthcare company and diagnostics leader in Canada. In May 2021, it signed a supplier distribution agreement to expand the distribution of Abbott’s Afinion 2™ and associated tests for diabetes and heart disease screening in community pharmacies in Canada. This agreement includes valuable HbA1c testing, a critical marker for the screening and management of diabetes.

Near term goals for the company include expansion into more pharmacies across Canada, followed soon after by entering the US and UK markets. It has made significant strides in testing and developing its technology and is moving into the commercialization stage.

Strategic partnerships like Abbott and pharmacy-focused pilot opportunities advance Avricore closer to becoming an incredibly dominant player in the community diagnostics space. The company aims to make actionable health information more accessible for everyone by creating the world’s largest rapid testing network in pharmacy.

Avricore’s leadership team brings a diverse portfolio of expertise across healthcare and biotech industries as well as technology, finance and communications. Together, they share a common vision for moving pharmacy forward and have positioned the company for significant future growth and expansion.

Hector Bremner has over fifteen years of senior and executive experience across various industries, including international trade, natural gas, marketing and communications. He has owned and operated TOUCH Marketing, a boutique marketing and communication firm based in Vancouver, from 2007 to 2013.

Bremner has also served as the executive assistant to the Deputy Premier and Minister of Natural Gas Development, Responsible for Housing, as well as the Minister of International Trade and Minister of Small Business. In 2015, he joined Vancouver’s Pace Group Communications as VP of Public Affairs.

David Hall’s leadership spans five different companies. Aside from acting as Chairman and Director at Avricore, he is also currently the Chairman of RepliCel Life Sciences, a member of the board of TrichoScience Innovations, AdvantageBC and Providence Health Care Research Institute.

Hall also served as Chairman of Perceptronix Medical, Inc., Chief Financial Officer, Secretary & Treasurer of Angiotech Pharmaceuticals, Inc., President & Director at Newcastle Resources Ltd. and Chairman for LifeSciences British Columbia.

Kiki Smith has over 20 years of experience assisting private and public companies in the roles of accountant, corporate controller and CFO in mining, oil & gas, real estate, high technology, food production and investment fund management. She currently provides consulting services in M&A, financial reporting and regulatory compliance to several public and private companies across several investment sectors.

Smith is also a member of the Chartered Professional Accountants of British Columbia. She has a Bachelor’s degree in Economics from the University of British Columbia.

Rodger Seccombe is the co-founder and former CEO of HealthTab™ Inc. He has over 20 years of experience launching and running companies in software, healthcare technology and clean energy. Seccombe is a recognized industry expert in direct-to-consumer and point-of-care testing technology.

In 2006, he joined the start-up team at Canadian Bioenergy Corporation and helped pioneer the development of the renewable fuel industry in Canada. Before HealthTab™, he designed and developed cloud-based informatics systems currently in use by some of the world’s leading medical laboratories and instrument manufacturers.

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") is pleased to provide this corporate update on the Company's execution expanding its powerful chronic-disease screening and reporting platform, HealthTab.

On August 8 th , the Company announced a new Master Service Agreement and Statement of Work was signed with Shoppers Drug Mart pharmacies to significantly expand the HealthTab point-of-care testing platform to up to 450 locations nation-wide, with affiliated locations under the Loblaw family of brands being included.

"The team has been exceptional in deploying systems and we have already deployed more than half of the target locations," said Hector Bremner, Avricore Health's CEO. "We are on track to achieve the late-November target for full deployment."

Once a pharmacy has HealthTab onsite there is a period of training and acclimating teams with the workflow. Nevertheless, data from locations is indicating strong utilization and patient uptake, generating strong consumables-based revenues.

In fact, HealthTab already has positive cash-flow from operations and is expected to significantly ramp up gross revenues over the next 12 months yielding target margins and profitability by Q2 2023.

Supporting the optimism of strong and sustainable growth are the anticipated policy and funding announcements related to point-of-care in community pharmacy by the federal and provincial governments in the coming weeks and months. These changes and commitments will have a significant impact on sales volumes in 2023, not to mention demand from pharmacy groups to install HealthTab.

For example, on October 5 th , the Government of Canada tabled its Framework for Diabetes in Canada, which lays out an aggressive strategy to better screen, surveil, prevent, and manage this disease which currently costs $30 Billion CAD annually to treat. To find the details, please visit: https://www.canada.ca/en/public-health/services/publications/diseases-conditions/framework-diabetes-canada.html

Also, in addition to Alberta and Ontario, British Columbia recently announced their plan to expand the scope of pharmacy practice, which includes limited prescribing as of October 14 th , and makes further commitments to work with the profession to identify additional ways they can contribute to healthcare solutions, such as chronic disease screening and support, as in other jurisdictions. To learn more, please visit: https://news.gov.bc.ca/releases/2022HLTH0059-001464

Internationally, policy and funding supporting more scope for pharmacists to tackle chronic disease and alleviate the pressures being faced for primary care also give a great deal of confidence that HealthTab's objective of being the world's leading point-of-care solution for pharmacy has a bright future. The coming weeks and months are expected to bring positive news and new opportunities for our current EU, UK and US program initiatives.

HealthTab™ is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab™ has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19. The HealthTab™ network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third-party app integration through API.

Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab™, a wholly owned subsidiary, the company's mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies.

Avricore Health Inc. Hector Bremner, CEO 604-773-8943 info@avricorehealth.com www.avricorehealth.com

Cautionary Note Regarding Forward-Looking Statements Information in this press release that involves Avricore Health's expectations, plans, intentions, or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release.

Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a few risks, uncertainties, and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy

News Provided by GlobeNewswire via QuoteMedia

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") is excited to offer a live discussion on the Company's current activities and forward outlook as it executes a significant national scale-up of its pharmacy-based point-of-care platform, HealthTab.

"We're currently deploying a significant expansion of HealthTab systems and we're on track to achieve our revenue goals, as well as getting to cash flow positivity," said Avricore Health CEO, Hector Bremner. "It's an exciting time for the Company and we're looking forward to discussing the recent successes and future objectives." Call Details: September 22, 2022 @ 11:00am PT / 2:00pm ET via Zoom Register here to receive login details: Investor@avricorehealth.com Agenda: The 60-minute call agenda will be as follows: 10min: Opening Remarks / Team Introductions 30Min: Overview Presentation and Update 20Min: Q&A We're looking forward to seeing you there, please review our most recent investor presentation here: www.avricore.com

HealthTab™ is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab™ has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19. The HealthTab™ network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third-party app integration through API.

Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab™, a wholly owned subsidiary, the company's mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies.

Avricore Health Inc. Hector Bremner, CEO 604-773-8943 info@avricorehealth.com www.avricorehealth.com

Cautionary Note Regarding Forward-Looking Statements Information in this press release that involves Avricore Health's expectations, plans, intentions, or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a few risks, uncertainties, and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy

News Provided by GlobeNewswire via QuoteMedia

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") was honoured to join the Globe and Mail's recent Health Care Innovation event, featuring leaders from various corners of the sector, including Company CEO, Hector Bremner.

"With about 40% of patients in Canada saying it's difficult to access a diagnostics test and nine million expressing difficulty in getting access to care, it's clear that the time is now to support more services in community pharmacy," says Avricore Health Inc. CEO, Hector Bremner. "HealthTab is already playing a significant role in supporting better services in pharmacy and we're going to continue to advocate for patients, and providers, so better outcomes for all are achieved."

The Globe and Mail's event featured health sector leaders, academics, governmental agency representatives, physicians, and patient advocates. For a full list of participants and to watch the webcast in its entirety, it can be viewed at the Globe and Mail's site at the following link: https://www.theglobeandmail.com/events/article-new-approaches-to-health-care-delivery/ .

Also, for reference to the above-mentioned observations on Canadian patient experience and sentiment around the current healthcare challenges, please view the recent Angus Reid Institutes series of polling data here: https://angusreid.org/canada-health-care-issues/ .

HealthTab™ is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab™ has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19. The HealthTab™ network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third-party app integration through API.

Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab™, a wholly owned subsidiary, the company's mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies.

Avricore Health Inc. Hector Bremner, CEO 604-773-8943 info@avricorehealth.com www.avricorehealth.com

Cautionary Note Regarding Forward-Looking Statements Information in this press release that involves Avricore Health's expectations, plans, intentions, or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a few risks, uncertainties, and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy.

News Provided by GlobeNewswire via QuoteMedia

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") is pleased to provide this corporate update on the Company's Q2 results.

"We have now begun a new era for Healthtab™ and the Company as we expand Shoppers Drug Mart significantly over the coming weeks," said Hector Bremner, CEO of Avricore Health Inc. "We are now realizing our revenue targets and are on track to realize long-term profitability as we continue to successfully execute our plan."

The following table highlights selected unaudited consolidated financial data for each of the eight most recent quarters that, in management's opinion, have been prepared on a basis consistent with the audited consolidated financial statements for the year ended December 31, 2021. These results are not necessarily indicative of results for any future period and you should not rely on these results to predict future performance.

RESULTS OF OPERATIONS FOR THE THREE MONTHS ENDED JUNE 30, 2022

The Company incurred comprehensive loss of $207,363 for the three months ended June 30, 2022 (2021 - $344,620) a decrease of 40%.

Significant changes are as follows:

Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab™, a wholly owned subsidiary, the company's mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies.

HealthTab™ is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues. With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab™ has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19. The HealthTab™ network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third-party app integration through API.

Avricore Health Inc. Hector Bremner, CEO 604-773-8943 info@avricorehealth.com www.avricorehealth.com

Cautionary Note Regarding Forward-Looking Statements Information in this press release that involves Avricore Health's expectations, plans, intentions, or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements. In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a few risks, uncertainties, and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy.

News Provided by GlobeNewswire via QuoteMedia

Avricore Health INC. (TSXV: AVCR) (the " Company " or " AVCR ") is pleased to announce that the Company's board of directors has approved the granting of stock options (the "Options") exercisable for a total of 2,725,000 common shares to its directors, officers, and consultants at an exercise price of CAD$0.15 per common share.

All Options were granted pursuant to the Company's stock option plan and are subject to the terms of the applicable grant agreements and the requirements of the TSX Venture Exchange.

The options are subject to a 1-year vesting period, with ¼ of the options vesting 3 months after the date of the grant and the remaining options vesting on a quarterly basis thereafter. The options expire 5 years from the date of the grant, subject to the optionees continuing to act as directors, officers or consultants of the Company.

HealthTab is a turnkey point-of-care testing solution that combines best-in-class point-of-care technologies with a secure, cloud-based platform for tackling pressing global health issues.

With just a few drops of blood from a finger prick, the system generates lab-accurate results on the spot and data is reported in real time. The test menu includes up to 23 key biomarkers for screening and managing chronic diseases, such as diabetes and heart disease (e.g., HbA1c, Lipid Profile, eGFR). HealthTab has also recently added capabilities for bacterial and viral tests, such as strep and COVID-19.

The HealthTab network model is unlike anything in pharmacy today. It gives knowledgeable and trusted pharmacists a greater role in primary care delivery, while empowering patients to take more control of their health. It also reduces costs and waiting times and provides many potential revenue streams including equipment leasing & consumables, direct access testing, disease prevention & management programs, sponsored health programs, decentralized clinical trials, real world data (RWD) sets, and third-party app integration through API.

To find a location near you, please visit: healthtab.com/locations

Avricore Health Inc. (TSXV: AVCR) is a pharmacy service innovator focused on acquiring and developing early-stage technologies aimed at moving pharmacy forward. Through its flagship offering HealthTab™ (a wholly owned subsidiary), its mission is to make actionable health information more accessible to everyone by creating the world's largest network of rapid testing devices in community pharmacies.

Avricore Health Inc. Hector Bremner, CEO 604-773-8943 info@avricorehealth.com www.avricorehealth.com

Cautionary Note Regarding Forward-Looking Statements Information in this press release that involves Avricore Health's expectations, plans, intentions or strategies regarding the future are forward-looking statements that are not facts and involve a number of risks and uncertainties. Avricore Health generally uses words such as "outlook," "will," "could," "would," "might," "remains," "to be," "plans," "believes," "may," "expects," "intends," "anticipates," "estimate," "future," "positioned," "potential," "project," "remain," "scheduled," "set to," "subject to," "upcoming," and similar expressions to help identify forward-looking statements.

In this press release, forward-looking statements include statements regarding: the completion of the placement and the expected timing thereof and the Company's expected use of proceeds from the placement; the unique features that the HealthTab™ platform offers to pharmacists and patients. Forward-looking statements reflect the then-current expectations, beliefs, assumptions, estimates and forecasts of Avricore Health's management. The forward-looking statements in this press release are based upon information available to Avricore Health as of the date of this press

release. Forward-looking statements believed to be true when made may ultimately prove to be incorrect. These statements are not guarantees of the future performance of Avricore Health and are subject to a number of risks, uncertainties and other factors, some of which are beyond its control and may cause actual results to differ materially from current expectations, including without limitation: failure to meet regulatory requirements; changes in the market; potential downturns in economic conditions; and other risk factors described in Avricore's public filings. These forward-looking statements speak only as of the date on which they are made, and the Company undertakes no obligation to update them publicly to reflect new information or the occurrence of future events or circumstances, unless otherwise required to do so by law.

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy.

News Provided by GlobeNewswire via QuoteMedia

Graphene Manufacturing Group Ltd. (TSXV: GMG) ("GMG" or the "Company") is pleased to provide the latest progress and performance update on its Graphene Aluminium-Ion Battery technology ("G+AI Battery") being developed by GMG and the University of Queensland ("UQ") and the GMG battery grade graphene production quality program.

Notably, this update includes information about GMG's G+AI Battery regarding:

Ongoing development from GMG's Battery Team has resulted in a significant increase in battery performance of GMG's Graphene Aluminium-Ion Battery. Latest testing data has demonstrated a calculated energy density that has increased by 93% from 150-160 Wh/kg to 290-310 Wh/Kg since the last battery update on the 22nd of June 2021 ("PreviousAnnouncement").

Performance data presented in this release was calculated off GMG's specific coin cell design and testing data, which has been separately verified by the Australian Institute for Bioengineering and Nanotechnology at the UQ as against other aluminium ion batteries and two commonly used lithium-ion batteries produced and used worldwide (see table and graph below).

Source: (1) Hongjie Dai, Nat. Commun., 2017, 8:14283, (2) Hongjie Dai, Nature, 2015, 520, 325, (3) and (4). University of Queensland validated GMG testing data.* (5). CATL 3.2V 150Ah LiFePO4 Battery Cell - LiFePO4 Battery (lifepo4-battery.com) on 29/09/22 (6). CATL 3.7V 65Ah NCM Lithium Battery Cell - LiFePO4 Battery (lifepo4-battery.com) on 29/09/22 7 *GMG testing data is based on industry standard estimate methodology - using a reducing factor of 2.3.

Energy Density (wh//kg) To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/8082/140087_graphenefigure1.jpg

Source: (1) Hongjie Dai, Nat. Commun., 2017, 8:14283, (2) Hongjie Dai, Nature, 2015, 520, 325, (3) and (4). University of Queensland validated GMG testing data.* (5). CATL 3.2V 150Ah LiFePO4 Battery Cell - LiFePO4 Battery (lifepo4-battery.com) on 29/09/22 (6). CATL 3.7V 65Ah NCM Lithium Battery Cell - LiFePO4 Battery (lifepo4-battery.com) on 29/09/22 7 *GMG testing data is based on industry standard estimate methodology - using a reducing factor of 2.3.

GMG's CEO Craig Nicol stated, "These results show the promise of GMG's Graphene Aluminium-Ion Battery in terms of performance on top of previously announced longevity and sustainability advantages. The outcome was the result of a large piece of work done by GMG's Battery Team to repeatably make successful batteries, improve almost all of the various components of the battery and the successful transfer of intellectual property from the UQ team."

Guy Outen, GMG's Chair added, "I'm delighted with this battery performance update which reflects both the tremendous creativity and hard work of all involved as well as the possibilities of our G+Al Batteries, even at this early stage in their development. This is a significant step in the development of our G+AI batteries and we look forward to the next steps towards commercialisation."

This performance improvement is a result of increasing the two main parameters since the Previous Announcement of:

The following chart shows this latest performance achieved:

To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/8082/140087_d6db8023e429d99c_004full.jpg

Source: GMG testing. All testing was carried out on coin cells with GMG Graphene in Aluminium Ion Battery at ambient temperature cycling from 2.7V to 0.5V, 4.5 Coulomb (2.2A/g) charge rate

This improvement in performance was associated with GMG successfully transferring the intellectual property from UQ's laboratories to GMG's Battery Development Centre and Battery Team. GMG now achieves a higher success and pass rate for the cells it makes for development and testing purposes which is a step towards commercial production.

Figure 1: Typical G+AI Battery Coin Cell Design

To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/8082/140087_d6db8023e429d99c_006full.jpg

GMG's Battery Team has conducted work across the entire cell design (as per Figure 1) to improve performance, longevity, and ease of manufacture assembly including:

Repeatable Battery Grade Graphene Quality

GMG's CEO Craig Nicol stated, "The Company's confidence is growing in the GMG developed scalable process to make graphene from natural gas to a definable and tuneable graphene type for the GMG G+AI Battery in a repeatable fashion. Further testing is planned in the near term to further validate this confidence."

GMG has also assessed battery performance with several different grades of GMG produced graphene using industry standard tests and have demonstrated repeatable and reproducible performance. GMG has increasing confidence that it has found an economically sustainable path to scale the graphene process. On this basis the Company will continue to work towards a final investment decision for first battery production.

GMG also compared the performance of the GMG made graphene, to graphene made by other processes by several other companies and identified GMG's graphene as having more favourable specific discharge capacity, ie. a higher energy density performance. The Company expects ongoing iteration and improvement over time of both the graphene quality from the GMG graphene production process, as well as the G+AI Battery performance as GMG further develops, deploys and scales both of these technologies.

G+AI Coin Cell Development

The next steps for the coin cells (as seen in Figure 2) are to undertake further engineering and development activities to achieve a coin cell capacity for the desired product application(s) being targeted for initial customer sales.

Figure 2: G+AI Coin cell prototypes.

To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/8082/140087_d6db8023e429d99c_007full.jpg

If this is achieved, subject to government approvals the Company's Board will consider a Final Investment Decision ("FID") for an automated coin cell factory and any (further) graphene production capacity expansion required. As part of the FID, GMG's Board considerations will include, but not be limited to, binding customer sales contracts, the economic costs to build an automated coin cell factory and other operational-level production considerations. GMG is targeting a FID decision in 2023 and the latest production to commence in 2024.

As a precursor, GMG has already committed to invest AU$1.5 million into expanding and relocating its graphene production operations into an adjacent warehouse to its existing headquarters and Battery Development Centre (totalling 3,500 square meters) in Richlands, Queensland, Australia, as announced by GMG on 17 August 2022.

G+AI Pouch Cell Development

The next development steps for the pouch cell (as seen in Figure 3) will follow a similar sequence to the initial development of the coin cell.

When completed GMG will look to update the Technology and Product Road Map for the pouch cell and finalise the end application(s) for the initial market/customer for the pouch cells and therefore finalise the targeted pouch cell capacity. The Company continues to work under confidentiality agreements with a range of potential customers as input to this decision.

Figure 3: GMG Pouch Cell Prototype.

To view an enhanced version of this graphic, please visit: https://images.newsfilecorp.com/files/8082/140087_d6db8023e429d99c_009full.jpg

Upon finalising the target market, size and location of the plant and after various conditions are met, the Company may take FID on an integrated gas to graphene and automated pouch cell factory at likely a new location to account for its potential scale. The Company hopes to make significant progress on the pouch cell in 2023.

GMG is a disruptive Australian-based clean-tech company listed on the TSXV (TSXV:GMG) that produces graphene and hydrogen by cracking methane (natural gas) instead of mining graphite. By using the company's proprietary process, GMG can produce high quality, low cost, scalable, 'tuneable' and no/low contaminant graphene - enabling demonstrated cost and environmental improvements in a number of world-scale planet-friendly/clean-tech applications. Using this low input cost source of graphene, the Company is developing value-added products that target the massive energy efficiency and energy storage markets.

The Company is pursuing additional opportunities for GMG Graphene, including developing next-generation batteries, collaborating with world-leading universities in Australia, and investigating the opportunity to enhance the performance of lubricant oil and performance enhanced HVAC-R coating system.

For further information, please contact:

- Craig Nicol, Chief Executive Officer, and Managing Director of GMG craig.nicol@graphenemg.com +61 415 445 223

- Leo Karabelas at Focus Communications Investor Relations (FCIR) leo@fcir.ca +1 647 689 6041

Cautionary Note Regarding Forward-Looking Statements

This press release contains "forward-looking information" and "forward-looking statements" within the meaning of applicable securities legislation. The forward-looking statements herein are made as of the date of this press release only, and the Company does not assume any obligation to update or revise them to reflect new information, estimates or opinions, future events or results or otherwise, except as required by applicable law. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budgets", "scheduled", "estimates", "forecasts", "predicts", "projects", "intends", "targets", "aims", "anticipates" or "believes" or variations (including negative variations) of such words and phrases or may be identified by statements to the effect that certain actions "may", "could", "should", "would", "might" or "will" be taken, occur or be achieved. Forward-looking information in this press release includes, but is not limited to, statements relating to the testing and validation of the graphene quality produced in the Company's production process, the economical sustainability of scaling the graphene and battery production processes, the ongoing improvement of graphene quality from the GMG graphene production process and the G+AI Battery performance, the engineering and development of the coin cell and pouch cell with respect to the current battery performance estimates and calculations, the timing and considerations of potential FIDs, anticipated timelines for commercial production, anticipated next steps for the further development of the Company's products, the development and viability of GMG's production facilities, and the location of GMG's production facilities. Forward-looking statements and information are subject to various known and unknown risks and uncertainties, including, but not limited to, the deployment of the Company's resources, that the Company will not be able to test or validate the battery grade quality of graphene needed for its products, that it will not be economically sustainable to scale the graphene or battery manufacturing processes, that the quality of the graphene manufactured by GMG and the performance of the G+AI Battery will not set out to be as estimated, calculated or improve, that the Company will not be able to further develop the coin cell and pouch cell technologies, and the timing or results of any FID. Such risk factors may cause the Company's actual results, performance or achievements to be materially different from those expressed or implied thereby, and are developed based on assumptions about such risks, uncertainties and other factors set out herein, including, assumptions regarding the Company's ability to research, develop and test its products within anticipated timelines, and that results of testing and development data will be consistent with anticipated results and estimates, and the market demand for the Company's products. Such forward-looking information represents management's best judgment based on information currently available. No forward-looking statement can be guaranteed and actual future results may vary materially. Accordingly, readers are advised not to place undue reliance on forward-looking statements or information.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/140087

News Provided by Newsfile via QuoteMedia

As technology continues to evolve, new investment opportunities are cropping up.

Sometimes called disruptive technologies, emerging technologies can be defined as tech sector segments that are set to massively impact human lives in the next decade.

This umbrella covers many types of technology, but a few of the best-known categories are artificial intelligence (AI), robotics and mobile. Read on for a look at the emerging technology space and how investors can jump into those three specific arenas.

As mentioned, AI is a key part of the emerging technology space, and some of the biggest growth is forecast in this segment. In fact, the market is predicted to reach a market value of US$1.81 trillion by 2030, growing at a compound annual growth rate (CAGR) of 38.1 percent between 2022 and 2030.

A report published by Grand View Research highlights that the advent of big data and demand for image processing and identification technology are set to fuel the growth of AI.

Click here to learn how to invest in AI.

Robotics has been tipped to achieve a market value of US$149.86 billion by 2030. A report by Allied Market Research states that the segment will witness a CAGR of 27.7 percent between 2021 and 2030.

Robotics technology has a wide range of applications across various industries, including healthcare, agriculture and manufacturing. The increasing need for automation and safety in these industries, along with the availability of affordable, energy-efficient robots, is the main driver of growth.

Click hereto learn how to invest in robotics.

Then of course there’s mobile technology, which encompasses everything from smartphones to tablets to laptop computers. In short, it’s technology that can follow users wherever they go.

With mobile devices becoming more integrated into everyday life, it's no surprise that projections for this market are riding high. However, because the space encompasses so many types of technology, it’s difficult to grasp exactly how much it could grow.

For instance, the mobile application market is expected to reach a value of US$565.4 billion by the end of 2030; meanwhile, the global mobile wallet market is projected to hit US$51.53 billion by 2030. All in all, there are a plethora of opportunities in the mobile technology space that investors could be able to get in on.

Click hereto learn how to invest in mobile technology.

For investors looking to enter the emerging technology space, stocks are the obvious choice. And considering that emerging technologies involve multiple sections of the tech sector, there’s certainly no shortage of companies for investors to look at.

As a starting point, check out our lists of stocks in the AI, robotics and mobile spaces:

For investors who want to put money into the emerging tech space as a whole rather than a specific company involved in the sector, exchange-traded funds (ETFs) are a popular way to go.

They provide exposure to a basket of products, such as stocks, and reduce risk by ensuring that investors are not overexposed to any one asset. To find out about some of the ETFs on offer in the AI and robotics segments, check out our lists below:

Overall, it’s clear that emerging technology will impact the future in diverse ways, and investors have plenty of options to consider.

This is an updated version of an article first published by the Investing News Network in 2017.

Don’t forget to follow us @INN_Technology for real-time news updates!

Securities Disclosure: I, Melissa Pistilli, hold no direct investment interest in any company mentioned in this article.

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) ("Bloom" or the "Company"), a leading provider of diagnostic and health technology services, announces a leadership transition.

Effective September 30, 2022, Andrew Morton has stepped down as CEO of the Company to pursue other opportunities. Rosemary Elliston, COO of the Company, has been appointed to the position of Interim CEO. Mr. Morton will continue to support the Company as a Director.

Ms. Elliston, an experienced healthcare executive, brings expertise in organizational planning, team development, multimillion-dollar capital projects, and increasing visibility for growth. "I am looking forward to working with Andrew and the rest of the Board to leverage the strong initial growth period that the Company has been able to achieve and continue to transition the Company into new market opportunities and further add to shareholder value", said Rosemary Elliston, Interim CEO. "Diagnostic and health tech services is a large and rapidly growing sector and our goal is to be at the forefront of it."

The Board of Bloom would like to thank Andrew for his hard work and dedication, delivering strong operating results throughout fiscal 2022 and positioning the Company for its next phase of growth. The Board of Directors, Bloom staff and Ms. Elliston are committed to business continuity and a smooth transition, including ongoing communications to our shareholders and investors.

"We're excited about the next phase of growth for Bloom, as the Company develops additional service offerings," said Andrew Morton, outgoing CEO. "As a director of the Company, I look forward to continuing to support the team in executing on this transition."

About Bloom Health Partners Inc.

Bloom Health Partners Inc. (CSE: BLMH) (OTCQB: BLMHF) (FSE: D840) is a global platform for diagnostic testing. Our mission is to ensure that "unstoppable is possible" for businesses and their employees through innovative, customized healthcare models.

For more information: info@bloomhealthpartners.com

On behalf of Bloom Health Partners Inc.

Rosemary Elliston Interim Chief Executive Officer

This news release includes forward-looking statements that are subject to risks and uncertainties. All statements within, other than statements of historical fact, are to be considered forward looking. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in forward-looking statements. Factors that could cause actual results to differ materially from those in the Company's forward-looking statements include the potential that milestones may not be satisfied, acquisitions may not achieve expected benefits, financing requirements, and the other risk factors described in the Company's filings with Canadian securities regulators on www.sedar.com. There can be no assurances that such statements will prove accurate and, therefore, readers are advised to rely on their own evaluation of such uncertainties. We do not assume any obligation to update any forward-looking statements except as required under the applicable laws.

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/139359

News Provided by Newsfile via QuoteMedia

PowerTap Hydrogen Capital Corp. (NEO: MOVE) (FWB: 2K6) (OTC: MOTNF) ("PowerTap" or the "Company" or "MOVE") is pleased to provide an update and details on Progressus Clean Technologies Inc. ("Progressus") entering into a letter of intent with Alkaline Fuel Cell Power Corp. (NEO: PWWR) (OTCQB:ALKFF) (Frankfurt: 77R, WKN: A3CTYF) ("AFCP") to complete a joint venture ("JV") pilot project that aims to provide a solution for natural gas utilities to directly power both residential and commercial businesses. AFCP is a diversified investment platform developing affordable, renewable, and reliable energy assets and cleantech. The JV is intended to provide proof of concept for each company's technologies and assess the ability to combine various Progressus technologies with AFCP fuel cells to serve residential and small building customers across North America. PowerTap owns 49% of Progressus.

"The missions and combined vision of AFCP and Progressus are very complementary to one another. By leveraging the strengths of both organizations, we can more efficiently and effectively solve the growing need for innovative hydrogen solutions. The proposed JV pilot project with AFCP is an active step towards progressing hydrogen innovation and combining the suite of technologies that will ultimately be needed for global hydrogen solutions in the future," said Channce Fuller, Chief Executive Officer of Progressus.

Raghu Kilambi, Chief Executive Officer of PowerTap, the 49% parent company of Progressus added, "We are very pleased with the development of Progressus' business since our initial investment in Progressus as initially announced on July 27, 2021 (1) ."

Conceptual Description of the Pilot Project

To reduce CO2 emissions around the world, gas distribution companies and municipalities are setting-up projects to inject hydrogen into the local gas distribution grid. This gas mixture generally aims to contain up to 20% hydrogen and its use is targeted for residential and commercial buildings.

AFCP and Progressus will work together to execute a JV pilot project utilizing technologies from each company to provide in-field proof-of-concept, generate operational data that can inform continued development and market opportunities, and establish a platform to support future potential growth and additional partnerships. The exact location of the JV pilot project remains under consideration but, initially, North America will be the focus with secondary priority given to potential future pilots in Europe.

Progressus' technology enables the extraction of dilute hydrogen from gas streams, a critical component as utility companies globally increasingly strive to inject hydrogen into natural gas streams. Progressus represents a solution that can extract the hydrogen at high efficiencies, complementing AFCP's low-cost combined heat and power alkaline fuel cell and generator development.

The JV pilot project is designed to use the Progressus hydrogen separation technology to efficiently extract hydrogen at high purities from the existing natural gas grid, and then convert the purified hydrogen using either AFCP's 4 kW Micro-CHP or 4 kW generator to produce electricity, and potentially heat. This project could be put to immediate use in a residential home or commercial building, providing truly zero-emission power. AFCP has already identified interest from natural gas and electric utilities and municipalities to pilot the concept.

Combining the technologies from both companies offers an ideal potential solution to support the generation of low carbon energy that contributes to the world's clean energy transition.

The energy sector currently accounts for approximately three-quarters of global greenhouse gas emissions and is therefore simultaneously capable of averting the worst effects of climate change ( 2 ) . To reduce CO2 emissions, gas distribution companies and municipalities are advancing projects that facilitate the injection of hydrogen into the local gas distribution grid as a cleaner energy source.

In the last two years alone, there have been more than two dozen hydrogen injection projects announced in the United States with companies continuing to reinforce additional commitments in early 2022 ( 3 ) . Further, with the passing of the Inflation Reduction Act (IRA), there is massive momentum building for additional investment in clean hydrogen solutions. Beyond the United States, the largest gas utilities around the globe (SoCalGas, Enbridge, ATCO Gas, Snam SpA, Enagas S.A., and Open Grid Europe to name a few) are all actively working on projects to inject hydrogen into their natural gas grids ( 4 ) .

The proposed pilot project would initially cover one extraction system linked to one 4 kW Micro-CHP or generator system, with expansion to a larger scale in future pilots designed to provide clean hydrogen and power for multiple residential users or commercial applications.

(1) https://www.globenewswire.com/en/news-release/2021/07/27/2269066/0/en/PowerTap-Acquires-49-of-AES-100-Inc-a-Green-Hydrogen-Technology-Company-Focused-on-Fuel-Cells-for-the-Transportation-Industry.html (2) https://www.un.org/en/climatechange/net-zero-coalition (3) https://www.spglobal.com/marketintelligence/en/news-insights/latest-news-headlines/gas-utilities-get-to-work-piloting-hydrogen-use-in-distribution-systems-69302367 (4) https://www.reuters.com/business/cop/europes-gas-firms-prime-pipelines-hydrogen-highway-2021-11-18/

Further to the Company's new release dated July 30, 2021 , the Company announces that it will issue an aggregate of 4,576,600 common shares at a deemed price of $0.10 per share pursuant to an agency agreement entered into with Mulberry Capital Inc. ("Mulberry") on October 18, 2021 and July 28, 2021 (the "Agency Agreement"). Mulberry is the Company's exclusive agent with the right to arrange, negotiate and obtain representation for sales in the Middle East. The issuance of shares is being made in lieu of a USD $350,000 cash payment for the first-year anniversary payment due under the Agency Agreement. The common shares are subject to a four month and one day hold period from the date of issuance and are subject to the Neo Exchange's acceptance of final filing documents.

On August 17, 2022, the Company issued an aggregate of 361,453 common shares at a deemed price of $0.29 per share pursuant to the Racing Sponsorship Agreement with Steinbrenner Racing, LLC and Defrancesco Motorsports Inc. The share issuance represented the final payment due for the 2023 sponsorship year. The securities were issued with a four month and one day hold period that will expire on December 18, 2022.

The Company also announces that pursuant to its shareholder approved restricted share unit plan (the "RSU Plan"), it has granted an aggregate of 13,000,000 restricted share units ("RSUs") to consultants (the "Eligible Parties") of the Company on September 16, 2022. The RSUs vested on issuance. The RSUs shall entitle the Eligible Parties the ability to acquire one common share (a "Share") of the Company underlying each such RSU by delivering a notice of acquisition to the Company in accordance with the RSU Plan for a period of 5 years from issuance. In accordance with the RSU Plan, the RSUs were priced at $0.085 based on the previous days trading price.

Progressus Clean Technologies (formerly AES-100 Inc.) is a venture stage green technology company focused on the development of novel hydrogen generation and separation technologies. Progressus Clean Technologies owns the exclusive rights and intellectual property pertaining to the Advanced Electrolyzer System for the production of hydrogen from dilute syngas.

ABOUT POWERTAP HYDROGEN CAPITAL CORP.

PowerTap Hydrogen Capital Corp., through its wholly owned subsidiary, PowerTap Hydrogen Fueling Corp. ("PowerTap"), is focused on installing hydrogen production and dispensing fueling infrastructure in the United States. PowerTap's patented solution has been developed over 20 years. PowerTap is now commercializing its third-generation blue hydrogen product that will focus on the refueling needs of the automotive and long-haul trucking markets that lack hydrogen fueling infrastructure. There are currently under 100 operational publicly available hydrogen stations in the United States with most of the existing stations purchasing industrial hydrogen from industrial manufacturers and shipping hydrogen to individual stations via tanker trucks. www.PowerTapcapital.com www.PowerTapfuels.com

PowerTap Hydrogen common shares are listed on the NEO Exchange. Please visit the company's profile on the NEO Exchange website at https://www.neo.inc/en/live/security-activity/MOVE#!/market-depth .

Investor Contact: Tyler Troup, Circadian Group IR MOVE@circadian-group.com

PowerTap Contact: Raghu Kilambi raghu@hydrogenfueling.co +1 (604) 687-2038

NEITHER THE NEO EXCHANGE NOR ITS REGULATIONS SERVICES PROVIDER HAVE REVIEWED OR ACCEPT RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.

Notice Regarding Forward Looking Information:

This press release contains "forward-looking statements" or "forward-looking information" (collectively referred to herein as "forward-looking statements") within the meaning of applicable securities legislation. Such forward-looking statements include, without limitation, forecasts, estimates, expectations and objectives for future operations that are subject to a number of assumptions, risks and uncertainties, many of which are beyond the control of PowerTap. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur or be achieved.

Although the Company believes that the material factors, expectations and assumptions expressed in such forward-looking statements are reasonable based on information available to it on the date such statements were made, no assurances can be given as to future results, levels of activity and achievements and such statements are not guarantees of future performance. Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from any forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, Progressus' failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; the failure of the BioQuest and Progressus to enter into a definitive agreement related to the transaction proposed in the LOI; Progressus ' ability to raise the funding required to support its continued operations and the implementation of its business plan; the ability of Progressus to develop effective new products and receive required approvals; competitive factors, including customer acceptance of the Company's products; and dependence upon third-party vendors, including to manufacture its products.

The forward-looking information contained in this release is expressly qualified by the foregoing cautionary statements and is made as of the date of this release. Except as may be required by applicable securities laws, the Company does not undertake any obligation to publicly update or revise any forward-looking information to reflect events or circumstances after the date of this release or to reflect the occurrence of unanticipated events, whether as a result of new information, future events or results, or otherwise.

News Provided by GlobeNewswire via QuoteMedia

dynaCERT Inc. (TSX: DYA) (OTCQX: DYFSF) (FRA: DMJ) (" dynaCERT " or the "Company") is pleased to announce that yesterday the Windfall Ecology Centre, a Canadian non-profit social enterprise, has recognized Alectra Utilities Corporation ("Alectra") for its use of dynaCERT' s HydraGEN™ Technology to reduce the emissions and fuel costs of fleet vehicles.

Alectra is the largest municipally owned electric utility in Canada by customer base. See: https://alectrautilities.com/

Windfall Ecology Centre is an Aurora, Canada-based non-profit social enterprise dedicated to building sustainable communities. See: https://windfallcentre.ca/

dynaCERT congratulates Alectra for receiving the Most Innovative Leader Award at the Windfall Ecology Centre ClimateWise Business Network's annual sustainability symposium and awards event, held this year in Aurora, Canada. See York Region Sustainability Awards: https://windfallcentre.ca/yorkregionawards/

dynaCERT is a global company, based in Toronto, Canada, that manufactures and distributes Carbon Emission Reduction Technology. Last year, Alectra commenced a pilot program whereby thirteen (13) of the utility's fleet vehicles, which are equipped with dynaCERT's patented HydraGEN™ Technology, were closely monitored for the pilot program. dynaCERT' s HydraGEN™ Technology systems saved over 8,000 kilograms of CO 2 e and each vehicle reduced their diesel consumption on various utility vehicles by 230 litres, on average. With dynaCERT' s HydraGEN™ Technology, the pilot program results have shown that Alectra could reduce its carbon emissions and fuel costs by over ten percent (10%) based on Alectra's 2021 data of its entire fleet.

dynaCERT' s HydraGEN™ Technology, in the past, has been shown to achieve up to the following reductions:

"Windfall Ecology Centre is proud to introduce to our members the impressive results achieved by dynaCERT 's HydraGEN™ Technology," said Brent Kopperson, Executive Director and Founder. "We applaud Alectra for their innovation and foresight in advancing environmentally sustainable practices."

"In Ontario, Canada and globally, dynaCERT fosters private and public sector collaborations with organizations focused on innovation in order to achieve sustainability and make a difference in a tangible way," said Jim Payne, President and CEO of dynaCERT . "I congratulate Alectra for their commitment and leadership and commend the Windfall Ecology Centre for providing a forum for sustainability discussion among community partners, and recognition of work well done."

dynaCERT has received the Smart Sustainable Company Rating Seal after a rigorous analysis of Triple-A Analytics GmbH of Austria. This honourable distinction of dynaCERT and its HydraGEN™ Technology as it applies to the United Nations Sustainable Development Goals and United Nations Global Compact Principles, has been evaluated as "high," the highest global ranking in its category.

Serving more than one million homes and businesses in Ontario's Greater Golden Horseshoe area, Alectra Utilities is now the largest municipally-owned electric utility in Canada, based on the total number of customers served. Alectra contributes to the economic growth and vibrancy of the 17 communities which they serve by investing in essential energy infrastructure, delivering a safe and reliable supply of electricity, and providing innovative energy solutions. Alectra's mission is to be an energy ally, helping customers and communities to discover the possibilities of tomorrow's energy future.

dynaCERT Inc. manufactures and distributes Carbon Emission Reduction Technology along with its proprietary HydraLytica™ Telematics, a means of monitoring fuel consumption and calculating GHG emissions savings designed for the tracking of possible future Carbon Credits for use with internal combustion engines. As part of the growing global hydrogen economy, our patented technology creates hydrogen and oxygen on-demand through a unique electrolysis system and supplies these gases through the air intake to enhance combustion, which has shown to lower carbon emissions and improve fuel efficiency. Our technology is designed for use with many types and sizes of diesel engines used in on-road vehicles, reefer trailers, off-road construction, power generation, mining and forestry equipment. Website: www. dynaCERT .com .

Except for statements of historical fact, this news release contains certain "forward-looking information" within the meaning of applicable securities law. Forward-looking information is frequently characterized by words such as "plan", "expect", "project", "intend", "believe", "anticipate", "estimate" and other similar words, or statements that certain events or conditions "may" or "will" occur. In particular, information relating to the Windfall Ecology Centre, the Windfall Ecology Centre ClimateWise Business Network, the Most Innovative Leader Award, Alectra Incorporated and Alectra Utilities Corporation cannot be independently verified. Although we believe that the expectations reflected in the forward-looking information are reasonable, there can be no assurance that such expectations will prove to be correct. We cannot guarantee future results, performance of achievements. Consequently, there is no representation that the actual results achieved will be the same, in whole or in part, as those set out in the forward-looking information.

Forward-looking information is based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those anticipated in the forward-looking information. Some of the risks and other factors that could cause the results to differ materially from those expressed in the forward-looking information include, but are not limited to: uncertainty as to whether our strategies and business plans will yield the expected benefits; availability and cost of capital; the ability to identify and develop and achieve commercial success for new products and technologies; the level of expenditures necessary to maintain and improve the quality of products and services; changes in technology and changes in laws and regulations; the uncertainty of the emerging hydrogen economy; including the hydrogen economy moving at a pace not anticipated; our ability to secure and maintain strategic relationships and distribution agreements; and the other risk factors disclosed under our profile on SEDAR at www.sedar.com . Readers are cautioned that this list of risk factors should not be construed as exhaustive.

The forward-looking information contained in this news release is expressly qualified by this cautionary statement. We undertake no duty to update any of the forward-looking information to conform such information to actual results or to changes in our expectations except as otherwise required by applicable securities legislation. Readers are cautioned not to place undue reliance on forward-looking information.

Neither the Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of the release.

On Behalf of the Board Murray James Payne, CEO

View source version on businesswire.com: https://www.businesswire.com/news/home/20220930005150/en/

Jim Payne, CEO & President dynaCERT Inc. #101 – 501 Alliance Avenue Toronto, Ontario M6N 2J1 +1 (416) 766-9691 x 2 jpayne@ dynaCERT .com Investor Relations dynaCERT Inc. Nancy Massicotte +1 (416) 766-9691 x 1 nmassicotte@ dynaCERT .com

News Provided by Business Wire via QuoteMedia

BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) ("BriaCell" or the "Company") a clinical-stage biotechnology company specializing in targeted immunotherapies for cancer, is pleased to announce that its lead product candidate, Bria-IMT™, will be featured in three posters during the 2022 San Antonio Breast Cancer Symposium® taking place December 6-10, 2022 at the Henry B. Gonzalez Convention Center in San Antonio, Texas.

"Our mission is to find solutions for advanced breast cancer patients who do not respond to current treatments. We are thrilled for the opportunity to share our clinical findings with clinicians who treat similar, difficult-to-treat patients," stated Dr. Bill Williams, BriaCell's President & CEO.

All poster presentations will be held at Hall 1, Henry B. Gonzalez Convention Center, 900 E. Market Street, San Antonio, TX 78205 U.S.A. Details on the poster presentations are as follows:

Poster ID: P1-05-28 Date: Tuesday, December 6, 2022 Time: 5:00 PM - 6:15 PM

Poster ID: P3-07-12 Poster ID: P3-06-08 Date: Wednesday, December 7, 2022 Time: 5:00 PM - 6:15 PM

Following the presentations, copies of the posters will be posted on https://briacell.com/scientific-publications/ .

BriaCell is an immuno-oncology-focused biotechnology company developing targeted and effective approaches for the management of cancer. More information is available at https://briacell.com/ .

This press release contains "forward-looking statements" that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as "anticipate," "believe," "contemplate," "could," "estimate," "expect," "intend," "seek," "may," "might," "plan," "potential," "predict," "project," "target," "aim," "should," "will," "would," or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on BriaCell's current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. These and other risks and uncertainties are described more fully under the heading "Risks and Uncertainties" in the Company's most recent Management's Discussion and Analysis, under the heading "Risk Factors" in the Company's most recent Annual Information Form, and under "Risks and Uncertainties" in the Company's other filings with the Canadian securities regulatory authorities and the U.S. Securities and Exchange Commission, all of which are available under the Company's profiles on SEDAR at www.sedar.com and on EDGAR at www.sec.gov . Forward-looking statements contained in this announcement are made as of this date, and BriaCell Therapeutics Corp. undertakes no duty to update such information except as required under applicable law.

Neither Toronto Stock Exchange nor its Regulation Services Provider (as that term is defined in the policies of the Toronto Stock Exchange) accepts responsibility for the adequacy or accuracy of this release.

Company Contact: William V. Williams, MD President & CEO 1-888-485-6340 info@briacell.com

Media Relations: Jules Abraham Director of Public Relations CORE IR 917-885-7378 julesa@coreir.com

Investor Relations Contact: CORE IR investors@briacell.com

News Provided by GlobeNewswire via QuoteMedia

Investing News Network websites or approved third-party tools use cookies. Please refer to the  cookie policy for collected data, privacy and GDPR compliance. By continuing to browse the site, you agree to our use of cookies.